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Abstract
Food allergy is a life-threatening allergic disease that is increasing in prevalence with no approved 
curative therapy. Standard treatment of food allergy is limited to avoidance of the allergen and 
supportive management of allergic symptoms and anaphylaxis. Current research, however, has 
been focused on developing therapy that can modify the allergic immune response in both 
allergen-specific and non-specific methods. This review will provide an overview of these methods 
including oral immunotherapy, sublingual immunotherapy, epicutaneous immunotherapy, modified 
food protein vaccines, anti-IgE monoclonal antibody adjuvant therapy, Chinese herbs, and 
helminth therapy.
Introduction
Food allergy is a life-threatening allergic disease that is increasing in prevalence with no 
curative treatments currently. Estimates of the prevalence of food allergies vary among 
studies, but one meta-analysis of 6 studies on food allergies in children reported that the 
prevalence based on oral food challenge (OFC) ranged from 1–10.8% (Rona et al., 2007). A 
meta-analysis of 51 studies on the prevalence of food allergy estimates that the prevalence is 
more than 1–2% but less than 10%, because of methodological differences and the inherent 
uncertainty in diagnostic tests for food allergy (Chafen et al., 2010). According to a survey 
of data from the National Center for Health Statistics on children with food allergy, the 
prevalence has increased by 18% from 1997 to 2007, while hospitalizations for food allergy 
have also tripled in the last decade (Branum and Lukacs, 2009). Standard treatment of food 
allergy is limited to avoidance of the allergen and supportive management of anaphylaxis 
(Burks et al., 2011). Current research, however, has been focused on developing therapy that 
can modify the allergic immune response using both allergen-specific and non-specific 
approaches (Sicherer and Sampson, 2009). Allergen-specific immunotherapy includes oral 
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immunotherapy (OIT), extensively heated egg and milk diets (e.g., heat-denatured protein 
immunotherapy), sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT), 
and modified recombinant food protein vaccines. Non-specific allergen immunotherapy 
includes the Chinese herbal formulation (FAHF-2), anti-IgE monoclonal antibody, and the 
use of helminthes (Nowak-Wegrzyn and Sampson, 2011). These therapies are in various 
stages of development ranging from animal models to phase 1 and 2 clinical trials.
Mechanisms of Allergy and Tolerance to Foods
Food allergy is thought to stem from a failure of the immune system to develop tolerance 
after exposure to a food protein. The immune system within the gastrointestinal tract is the 
largest in the body and is responsible for distinguishing food protein antigens from 
pathogens and commensal flora, and mounting the appropriate immune response to each. 
Ingested food antigens are physically and chemically broken down during digestion, and 
then traverse the gut epithelium, where they are taken up and processed by an antigen 
presenting cell (APC), often a dendritic cell. Peptides from the antigen are processed and 
presented in the context of major histocompatibility (MHC) class II molecules on the surface 
of the APC for recognition by a T cell specific for that antigenic peptide. This interaction 
may result in T cell activation and differentiation or alternatively anergy. In animals, 
tolerance has been shown to develop when the APC-T cell interaction results in the 
production of antigen-specific regulatory T cells (Tregs), and these Tregs actively suppress 
other immune cells from reacting to food antigens; this occurs when naïve mice are fed low 
doses of antigen. A separate form of high-dose tolerance has also been described, in which 
the APC-T cell interaction results in anergy or deletion of the responder T cell (Vickery et 
al., 2011). Although the specific mechanisms of tolerance to food antigens in humans remain 
elusive, tolerance can be operationally defined as an active immune-mediated form of non-
responsiveness (as opposed to simple ignorance). Food allergy is thought to occur when 
these processes fail, and the result is allergic priming initiated and propagated by a 
pathologic T cell response. This allergic T cell response is known as the type 2 helper cell 
(Th2) response, in contrast to other T helper cell responses such as Th1, Th17, Th9, etc. Th2 
differentiation results from stable expression of the GATA-3 transcription factor and leads to 
the production of cytokines, such as interleukin-4 (IL-4), IL-5, and IL-13, that in turn 
stimulate production of immunoglobulin E (IgE) and activation of other effector pathways. 
Once this has occurred, the host will develop allergic reactions upon re-exposure to the same 
allergen. The deviation towards the allergic pathway can be influenced by a number of 
factors, including genetics, environmental factors, the intrinsic properties of the allergens 
themselves, as well as the nature and route of the allergenic exposure (Sicherer and 
Sampson, 2009; Otsu and Dreskin, 2011).
Allergen-specific Therapies
Similar to the subcutaneous injections of aeroallergens that have long been proven 
efficacious in allergic rhinitis, allergen-specific food immunotherapies aim to interrupt 
and/or reverse the immunologic events described above by introducing very small amounts 
of the allergen itself orally or sublingually in a controlled fashion. These therapies have been 
shown in randomized clinical trials to achieve immunomodulation (generally, reduction in 
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mast cell reactivity and allergen-specific IgE levels, accompanied by increases in allergen-
specific IgG4 levels) as well as desensitization, a state where consistent daily exposure to the 
allergen raises the dose at which a patient will react (Jones et al., 2009; Kim et al., 2011a; 
Skripak et al., 2008; Varshney et al., 2011). This is a major advance in the treatment of food 
allergy and it is possible that the oral allergen-specific approach will result in the first 
clinically-approved disease-modifying interventional treatment for food allergy in the 
coming few years. While desensitization decreases the likelihood of life-threatening 
reactions to accidental ingestions, it is a transient effect that depends entirely on daily 
exposure to the allergen. Furthermore, the individual’s exposure to the allergen is limited to 
only the daily dose (i.e., the diet cannot be liberalized). In contrast, true clinical tolerance 
would consist of a more permanent state allowing the subject to discontinue active therapy, 
with no reaction upon reintroduction of the allergen into the diet ad lib. It is important to 
note that clinical tolerance in humans has not been definitively linked to the immunologic 
tolerance described in the previous section; these terms are not interchangeable.
Oral immunotherapy
OIT consists of gradually escalating doses of allergen, administered orally in a food vehicle 
every day over months, with the goal of desensitization. Once a maintenance dose is 
achieved, the dose is not further escalated, and the individual continues to take the daily oral 
dose for a period of years. The proof of concept was first demonstrated in 1908, with a case 
report of a boy suffering from egg-induced anaphylaxis. However, scientific progress in the 
field remained stagnant until 1984, when Patriarca et al. (1984) attempted OIT to milk, fish, 
egg, and orange in 14 patients. Since this report, there have been a number of trials 
incorporating mechanistic studies that have investigated OIT with egg, milk, fish, and 
peanut, with some evidence of tolerating higher doses of allergen after immunotherapy, but 
most of these studies were limited by the lack of placebo-controlled groups for comparison 
(Blumchen et al., 2010; Jones et al., 2009; Longo et al., 2008; Meglio et al., 2004; Morisset 
et al., 2007; Patriarca et al., 2003; Staden et al., 2007). In 2008, the first blinded, 
randomized, placebo-controlled trial of OIT (Narisety et al., 2009; Skripak et al., 2008) 
demonstrated that active therapy suppressed mast cell activation and raised the median 
threshold for milk reactivity from 40 grams at baseline to 5,140 grams after therapy, 
compared to no change in controls. Placebo-controlled studies demonstrating robust 
desensitization and immune modulation to peanut and egg were subsequently published 
(Burks et al., 2012; Varshney et al., 2011). In summary, these studies have been 
characterized by certain trends, with 10–20% of patients failing desensitization due to 
allergic side effects, 10–20% achieving partial desensitization, and 50–75% achieving 
desensitization (Nowak-Wegrzyn and Sampson, 2011). Though there is some evidence that a 
majority of patients can achieve desensitization, this success is tempered by the high rate of 
adverse reactions. In one study of peanut OIT, 93% of participants experienced allergic 
symptoms during the initiation of OIT (Hofmann et al., 2009), although these were generally 
mild. OIT-induced anaphylaxis requiring epinephrine is uncommon.
Though allergen-specific therapies ultimately aim for clinical tolerance, none have been able 
to definitively prove the induction of tolerance. The study that comes closest to 
demonstrating tolerance is a recently published (Burks et al., 2012) multi-center, double-
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blind, randomized, placebo-controlled study of egg oral immunotherapy. At a planned 
interim analysis after 10 months of OIT, 22 of 40 (55%) of active subjects ingested 5 grams 
of egg during an OFC and were considered desensitized, compared to 0 of 15 in the placebo 
group. By 22 months of OIT, 75% of the active group had achieved desensitization, and 
underwent OFC again four to six weeks after stopping OIT. Ultimately, 28% of the active 
group developed a form of clinical tolerance the authors termed “sustained 
unresponsiveness,” defined as the ability to eat egg ad lib in the diet by months 30 and 36 
without symptoms. This is the first demonstration of a more permanent effect after OIT in a 
well-powered multi-center trial. However, spontaneous resolution is the expected natural 
history of egg allergy, and so it is conceivable that the participants might have outgrown 
their allergies even without OIT. The study was designed to minimize this possibility, and it 
was not frequently seen in the placebo group, although for safety reasons placebo subjects 
were not systematically challenged at all time-points. Overall, this study is one of the first to 
strongly suggest sustained unresponsiveness after OIT, an initial step in the pursuit of 
clinical tolerance. Much more investigation is necessary prior to concluding that 
reestablishing clinical tolerance to foods is a therapeutic possibility.
Extensively heated milk or egg
There is evidence that extensive heating of milk and egg, especially when mixed in a wheat-
based batter and baked, can alter the conformational allergen epitopes that bind IgE and 
mediate the allergic reaction (Cooke and Sampson, 1997). Although it has been known 
clinically that some egg and milk allergic patients can eat such baked foods but not less 
well-cooked forms, this phenomenon has been more rigorously investigated in recent years. 
These patients are distinguished as heated milk-tolerant or heated egg-tolerant. In contrast, 
patients who cannot tolerate any forms of the allergen (heated or unheated) are referred to as 
heated milk-reactive or heated egg-reactive. One study of 100 milk-allergic patients found 
that 75% of the children with reported milk allergy tolerated heated milk when tested by 
heated milk OFC (Nowak-Wegrzyn et al., 2008). A similar study in egg showed that of 117 
subjects with documented IgE-mediated egg allergy, 74% tolerated heated egg (Lemon-Mule 
et al., 2008). Among fifty heated milk-tolerant patients, none required epinephrine when 
challenged to unheated milk. In comparison, 35% of the 23 heated milk-reactive patients did 
require epinephrine during their unheated milk OFCs, suggesting that the heated milk-
tolerant patients develop less severe reactions when exposed to unheated milk. This may 
represent a milder food allergy phenotype, and interestingly the same group in other studies 
was shown to have less basophil reactivity and a higher number of milk-specific Tregs, 
compared to the heated-milk-reactive group (Shreffler et al., 2009; Wanich et al., 2009). 
When this cohort of 100 patients was followed over time, another analysis was conducted 
that suggests but does not prove that incorporation of baked milk products into the diet of 
heated milk-tolerant patients may accelerate the development of unheated milk tolerance 
(Kim et al., 2011b). This article showed that participants who incorporated baked milk into 
their diet were sixteen times more likely to become fully milk tolerant than the comparison 
group that practiced strict avoidance. This suggests that incorporation of heat-denatured 
proteins into the diet may have an immunotherapeutic effect.
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Prior to these studies, strict avoidance was the general recommendation for food-allergic 
patients, based on the idea that the complete absence of exposure would help hasten the 
onset of spontaneous natural tolerance. Without a true randomized prospective control 
group, it is difficult to conclude whether baked milk exposure truly acted therapeutically to 
increase the likelihood of developing tolerance, or if the more rapid improvement was 
simply due to a milder milk allergy phenotype than the comparison group. However, the 
introduction of extensively heated allergens was well-tolerated by the majority of subjects, 
challenging the paradigm of strict avoidance. Additional study of these modified proteins as 
immunotherapy is necessary.
Sublingual immunotherapy
There have been few trials of SLIT for food allergy, but they generally resemble the 
escalation and maintenance type of OIT trials described above, with the important exception 
that much smaller doses are administered under the tongue; for example, whereas 
maintenance doses in OIT may reach 2–4 grams of protein per day, SLIT maintenance doses 
may be only 2–4 milligrams per day. In 2003, the first case report of SLIT for a food 
allergen was published, describing a patient with anaphylactic reactions to kiwi (Mempel et 
al., 2003). Since then, studies have shown the use of SLIT in hazelnut and peach allergy, and 
these studies are notable for the use of placebo controlled comparison groups (Enrique et al., 
2005; Fernandez-Rivas et al., 2009). However, their inclusion criteria did not exclude 
subjects with oral allergy syndrome, and as these patients are at low risk for anaphylaxis, it 
is difficult to extrapolate their findings to patients with true systemic/gastrointestinal food 
allergy. One study evaluated the use of SLIT in milk allergic patients, indicating an increase 
in the dose tolerated, but this was limited by the lack of a control group (de Boissieu and 
Dupont, 2006). Kim et al. (2011a) reported the first double blind, placebo-controlled trial 
with 18 peanut-allergic children randomized to peanut or placebo SLIT demonstrating a 
favorable safety profile and an immune-modifying effect. Subjects receiving active treatment 
were able to ingest approximately twenty times more peanut protein than the control group 
prior to the onset of symptoms. A large multi-center randomized placebo-controlled trial is 
underway for peanut allergy, but has yet to report results. Because of its ease and safety, 
SLIT could be an attractive immunotherapeutic option, but much more study is needed to 
determine if it is effective.
A recent study compared SLIT and OIT in the treatment of 30 participants with milk allergy 
(Keet et al., 2012). The children were randomized to either SLIT only or SLIT followed by 
OIT at two different doses. After 60 weeks of maintenance therapy, 1 of 10 participants in 
the SLIT group achieved desensitization, compared to 6 of 10 patients in the lower-dose 
SLIT/OIT group and 8 of 10 patients in the higher-dose SLIT/OIT group. While the overall 
rate of allergic reactions was similar between SLIT alone and SLIT/OIT, the OIT group had 
more systemic reactions. Based on these findings, the group concluded that OIT was 
potentially more effective but also more prone to serious allergic reactions.
Epicutaneous therapy
EPIT involves the application of a patch containing a specific allergen onto the skin. In a 
small double blind, placebo-controlled pilot study, 18 children with milk allergy were 
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randomized to receive either a patch containing milk proteins or a placebo patch for three 
months (Dupont et al., 2010). By the end of the study period, patients in the active treatment 
group were able to ingest on average 23.6 ml of milk, compared to 1.8 ml at baseline. The 
amount of cow’s milk ingested in the placebo group did not change. Common side effects 
included local pruritus and eczema, with no severe systemic reactions. Peanut EPIT has also 
been studied in mouse models and currently phase 2 trials of peanut EPIT are ongoing 
(ClinicalTrials.gov, NCT01197053 and NCT01170286) (Mondoulet et al., 2011).
Modified food protein vaccines
Modified food protein vaccines involve the delivery of allergenic proteins that have 
undergone point mutations of key amino acids, in order to alter the epitopes that are 
responsible for binding IgE. Modification of these IgE binding epitopes decreases the 
affinity of this interaction and should in theory enhance the safety of this approach, 
compared to allergen-specific approaches with native proteins. Modified food proteins have 
been engineered for peanut, fish, and apple (Bannon et al., 2001; Ma et al., 2006; Rabjohn et 
al., 1999; Swoboda et al., 2007). Li et al. (2003b) coadministered subcutaneous injections of 
modified major peanut allergens Ara h 1, 2, and 3 with a bacterial adjuvant such as Listeria 
monocytogenes in mice previously sensitized to peanut. After four weeks of these injections, 
mice that had received the recombinant peanut protein had decreased anaphylactic 
symptoms in response to a peanut challenge compared to control mice. This treatment is 
believed to shift the immune response from the allergic Th2 pathway to a Th1 response, 
based on decreased IL-5 and IL-13 cytokine levels and increased interferon-gamma (IFN-
gamma) levels in splenocytes cultured from the modified peanut protein treated mice.
Other investigations have used nonpathogenic E. coli as an adjuvant and vector for the 
modified major peanut allergens Ara h 1, 2, and 3 (Li et al., 2003a). As E. coli normally 
colonizes the gut, the modified heat killed E. coli containing the mutated proteins was 
administered rectally in mice for 3 weeks. Mice challenged with peanut had decreased 
severity of anaphylaxis. Splenocytes isolated from these mice also produced decreased Th2 
cytokines and increased Th1 cytokines. Based on these findings, a phase 1 clinical trial 




Li and colleagues have developed a combination of Chinese herbs, known to have anti-
inflammatory properties in traditional Chinese medicine, which they are testing as a 
treatment for food allergy. In murine models of peanut allergy, seven weeks of treatment 
with food allergy herbal formula (FAHF-2) successfully prevented the development of 
anaphylaxis up to 5 weeks post therapy (Srivastava et al., 2005). Recent work in mice 
sensitized to multiple allergens, specifically fish, egg, and peanut, has shown that FAHF-2 
can block anaphylaxis in a non-allergen-specific way (Srivastava et al., 2012). An FAHF-2 
product was produced for use in humans in keeping with established FDA guidelines of 
safety and quality control, and standardization of the batches was verified using high-
Virkud and Vickery Page 6













performance liquid chromatography. A phase 1 randomized double blind placebo-controlled 
trial of FAHF-2 was completed with 19 patients and the herbal formula was shown to be safe 
and well tolerated (Wang et al., 2010). In this trial, the subjects were administered doses of 
up to 6.6 grams three times a day, with no apparent adverse effects. Phase 2 trials of FAHF-2 
are ongoing (Clinicaltrials.gov, NCT00602160). While the large number of pills (10 tablets 
3 times a day) is a potential limitation, this approach has the advantage of potentially 
treating multiple allergies at once.
Anti IgE monoclonal antibodies
Omalizumab is a humanized monoclonal antibody designed to bind IgE and block its 
interaction with high affinity IgE receptors that mediate the allergic reaction. The presence 
of drug-IgE complexes decreases the amount of free IgE, which leads to downregulation of 
these IgE receptors on mast cells and basophils. Omalizumab has been studied both as a 
non-specific immunotherapy and as an adjunct to allergen-specific immunotherapy; 
however, the first trial proving the efficacy of this therapy in food allergy was with a 
different anti-IgE antibody that has now been discontinued, TNX-901 (Leunget al., 2003). 
This double blind study involved 84 peanut-allergic participants, who underwent baseline 
peanut OFCs, were randomized to either four weeks of one of three different doses of 
TNX-901 or placebo, and then underwent repeat OFC. Only the highest dose had a 
statistically significant improvement, with a mean threshold for peanut ingestion of 2,805 
milligrams (approximately 9 peanuts), compared to 178 milligrams (about half of a peanut) 
in the control group. Of note, 24% of the patients receiving the highest dose of TNX-901 
had no significant change in the threshold for peanut, suggesting that not all peanut-allergic 
patients would respond to this therapy.
A randomized, double blind, placebo-controlled phase II trial was initiated to study the 
efficacy of omalizumab in treating peanut allergy (Sampson et al., 2011). The study intended 
to enroll 150 participants, but due to two severe anaphylactic reactions during preliminary 
screening OFCs, the study was terminated early. At that time, 26 subjects were randomized, 
with 17 receiving omalizumab. Preliminary results showed a trend towards greater doses of 
peanut tolerated in the active treatment group, but these were not statistically significant 
(p=0.054). Further investigation will be necessary to prove that omalizumab will be effective 
in increasing the threshold of reactivity to allergens.
Omalizumab has also been used as an adjunct to OIT in a recent study (Nadeau et al., 2011). 
This pilot study enrolled 11 children and pretreated them with omalizumab for 9 weeks, 
followed by desensitization to milk over 7 to 11 weeks. Ten subjects remained in the study 
and 9 of these passed the final OFC. The percentage of adverse reactions was similar to that 
of prior milk OIT trials. A number of additional small trials testing OIT and omalizumab are 
also currently underway (ClinicalTrials.gov).
Parasites
Helminth parasites elicit strong immunoregulatory responses upon infecting their host and 
thus are being increasingly studied as an immunotherapeutic treatment in a variety of 
diseases, including allergic disease. In 2002, Bashir et al. (2002) used a mouse model for 
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peanut-induced anaphylaxis and infected the mice with the helminth, Heligmosomoides 
polygyrus. The helminth-infected mice had significantly decreased symptoms in response to 
exposure to peanut, when compared to controls. The mechanism for this reduction in 
anaphylactic response appeared to be due to a decrease in IL-13 and increase in IL-10 
production. Another helminth that is being investigated for therapeutic efficacy is Trichuris 
suis, a helminth of the nematode family that naturally infects pigs (Jouvin and Kinet, 2012). 
T. suis ova therapy has been successfully used to improve disease severity in inflammatory 
bowel disease (Summers et al., 2005). Phase 1 trials assessing the safety of administering T. 
suis ova orally in 6 adults with peanut or tree nut allergy were recently completed (Jouvin 
and Kinet, 2012). Participants ingested 8 total doses of 2,500 ova each. Side effects were 
mostly mild self-limited gastrointestinal symptoms. Phase 2 trials for efficacy have not yet 
been started.
Conclusion
Food allergy is a life-threatening allergic disease that is rising in prevalence with no 
approved treatments at this time. However, current research is exploring a wide variety of 
therapeutic options, ranging from both allergen specific to non-specific techniques. This 
research not only focuses on the quest for food allergy therapy, but it also better elucidates 
our understanding of the mechanism of tolerance to food allergies. One or more of these 
techniques will likely prove successful in at least diminishing the severity of food allergies 
through desensitization and be approved for clinical use as a disease-modifying therapy. This 
development will change the standard of care for these individuals in a desperately needed 
way, and future studies will continue to refine therapy, with the ultimate goal of establishing 
durable clinical tolerance.
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